Cargando…

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond

CD1d-restricted invariant natural killer T (iNKT) cells are considered an attractive target for cancer immunotherapy. Upon their activation by glycolipid antigen and/or cytokines, iNKT cells can induce direct lysis of tumor cells but can also induce an antitumor immune response via their rapid produ...

Descripción completa

Detalles Bibliográficos
Autores principales:	King, Lisa A., Lameris, Roeland, de Gruijl, Tanja D., van der Vliet, Hans J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036112/ https://www.ncbi.nlm.nih.gov/pubmed/30013569 http://dx.doi.org/10.3389/fimmu.2018.01519

Ejemplares similares

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
por: Poels, Renée, et al.
Publicado: (2021)

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
por: Veluchamy, John P., et al.
Publicado: (2017)

Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses
por: Zhang, Lianjun, et al.
Publicado: (2017)

Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza
por: Barthelemy, Adeline, et al.
Publicado: (2016)

Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
por: Croudace, Joanne E, et al.
Publicado: (2008)

Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy
por: Bedard, Melissa, et al.
Publicado: (2017)

α-galactosylceramide-stimulated invariant natural killer T-cells play a protective role in murine vulvovaginal candidiasis by Candida albicans
por: Abe, Masahiro, et al.
Publicado: (2021)

Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions
por: Lameris, Roeland, et al.
Publicado: (2023)

Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer
por: Wang, Ying, et al.
Publicado: (2020)

Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α-Galactosylceramide-Stimulated Natural Killer T Cells
por: Lee, Sung Won, et al.
Publicado: (2013)

Mixed Signals: Co-Stimulation in Invariant Natural Killer T Cell-Mediated Cancer Immunotherapy
por: Shissler, Susannah C., et al.
Publicado: (2017)

Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies
por: Lam, Pui Yeng, et al.
Publicado: (2017)

Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15
por: Hsu, Chien-Ya, et al.
Publicado: (2021)

Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8(+) T Cell Responses via CD169(+) Macrophages and cDC1
por: Grabowska, Joanna, et al.
Publicado: (2021)

Invariant Natural Killer T and Mucosal-Associated Invariant T Cells in Asthmatic Patients
por: Lezmi, Guillaume, et al.
Publicado: (2018)

Immunometabolic Activation of Invariant Natural Killer T Cells
por: Ververs, Francesca A., et al.
Publicado: (2018)

CD1d-mediated Recognition of an α-Galactosylceramide by Natural Killer T Cells Is Highly Conserved through Mammalian Evolution
por: Brossay, Laurent, et al.
Publicado: (1998)

Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Attenuates the Development of Angiotensin II-Mediated Abdominal Aortic Aneurysm in Obese ob/ob Mice
por: Saito, Akimichi, et al.
Publicado: (2021)

Natural Killer T Cell Ligand α-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines
por: Gonzalez-Aseguinolaza, Gloria, et al.
Publicado: (2002)

α‐galactosylceramide generates lung regulatory T cells through the activated natural killer T cells in mice
por: Chen, Qianhui, et al.
Publicado: (2018)

Therapeutic Potential of Invariant Natural Killer T Cells in Autoimmunity
por: Van Kaer, Luc, et al.
Publicado: (2018)

Glucosylceramide Synthase Is Involved in Development of Invariant Natural Killer T Cells
por: Popovic, Zoran V., et al.
Publicado: (2017)

Harnessing invariant natural killer T cells to control pathological inflammation
por: Bharadwaj, Nikhila S., et al.
Publicado: (2022)

Insights Into Mucosal-Associated Invariant T Cell Biology From Studies of Invariant Natural Killer T Cells
por: Garner, Lucy C., et al.
Publicado: (2018)

Natural Killer T Cells in Cancer Immunotherapy
por: Nair, Shiny, et al.
Publicado: (2017)

Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
por: Saura-Esteller, José, et al.
Publicado: (2022)

Activation and Regulation of B Cell Responses by Invariant Natural Killer T Cells
por: Doherty, Derek G., et al.
Publicado: (2018)

Natural Killer T Cells and Mucosal-Associated Invariant T Cells in Lung Infections
por: Trottein, François, et al.
Publicado: (2018)

Impact of Aging on the Phenotype of Invariant Natural Killer T Cells in Mouse Thymus
por: Papadogianni, Georgia, et al.
Publicado: (2020)

Natural Killer T Cell Ligand α‐Galactosylceramide Inhibited Lymph Node Metastasis of Highly Metastatic Melanoma Cells
por: Nakui, Minoru, et al.
Publicado: (1999)

The Role of Invariant Natural Killer T Cells in Dendritic Cell Licensing, Cross-Priming, and Memory CD8(+) T Cell Generation
por: Gottschalk, Catherine, et al.
Publicado: (2015)

Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control
por: Kinjo, Yuki, et al.
Publicado: (2018)

Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor
por: Toffoli, Elisa C., et al.
Publicado: (2021)

Modeling Natural Killer Cell Targeted Immunotherapies
por: Lopez-Lastra, Silvia, et al.
Publicado: (2017)

Targeting Natural Killer Cells for Tumor Immunotherapy
por: Zhang, Cai, et al.
Publicado: (2020)

Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d
por: Clark, Katharine, et al.
Publicado: (2019)

The Influence of Invariant Natural Killer T Cells on Humoral Immunity to T-Dependent and -Independent Antigens
por: Lang, Mark L.
Publicado: (2018)

Invariant Natural Killer T Cell Subsets—More Than Just Developmental Intermediates
por: Krovi, S. Harsha, et al.
Publicado: (2018)

Activation of Invariant Natural Killer T Cells Redirects the Inflammatory Response in Neonatal Sepsis
por: Bolognese, Alexandra C., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pbhl0rtat68nvv62sfc364paak